   IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE

ROBERT G. BROWN,                         )
                                         )
            Plaintiff,                   )
                                         )
      v.                                 )    C.A. No. 2018-0687-MTZ
                                         )
LORRENCE T. KELLAR,                      )
CHRISTIAAN M. OLIVIER,                   )
ARTHUR B. DROGUE, JACK W.                )
PARTRIDGE, and R. ERIC                   )
MCCARTHEY,                               )
                                         )
            Defendants.                  )

                         Date Submitted: December 19, 2018
                          Date Decided: December 21, 2018

David J. Teklits and Elizabeth A. Mullin, MORRIS, NICHOLS, ARSHT &
TUNNELL LLP, Wilmington, Delaware; Attorneys for Plaintiff Robert G. Brown

Michael F. Bonkowski, Nicholas J. Brannick, and Bradley P. Lehman,
COLE SCHOTZ, P.C., Wilmington, Delaware; Attorneys for Defendants Lorrence
T. Kellar, Christiaan M. Olivier, Arthur B. Drogue, Jack W. Partridge, and
R. Eric McCarthey


ZURN, Vice Chancellor
        Plaintiff Robert G. Brown, a stockholder of SPAR Group, Inc. (“SGRP”),

brought this dispute to determine the composition of SGRP’s board of directors (the

“Board”) under 8 Del. C. § 225 (the “225 Action”). This opinion addresses (i)

Brown’s November 14, 2018, Motion for Summary Judgment (the “Motion for

Summary Judgment”),1 and (ii) SGRP’s December 13, 2018, Motion to Supplement

the Summary Judgment Record (the “Motion to Supplement”).2 The 225 Action is

on a dual track with an earlier action by SGRP against majority stockholders Brown

and William H. Bartels for declaratory judgment, conspiracy, and breach of fiduciary

duties (the “Bylaw Action”).3 The Bylaw Action seeks injunctive relief to prevent

the majority stockholders’ alleged entrenchment. The actions are scheduled for

consecutive expedited trials in January 2019, with a status quo order binding the

parties in the interim. The parties are currently engaged in discovery.

        In the 225 Action, Brown seeks a determination that certain written consents

he and Bartels delivered to the Board in July 2018 removed incumbent director

Lorrence T. Kellar and replaced him with non-party Jeffrey Mayer. Brown’s Motion

for Summary Judgment asserts that the written consents were technically valid and



1
 This decision refers to the parties’ briefing on the Motion for Summary Judgment as the
“Opening Br.,” “Answering Br.,” and “Reply Br.”
2
 This decision refers to the parties’ briefing on the Motion to Supplement as the “Mot. to
Supp.,” “Opp. to Mot. to Supp.,” and “Reply to Mot. to Supp.”
3
    C.A. No. 2018-0650-MTZ.


                                            2
effective upon delivery, and that, as a matter of law, the Court cannot expand its

scope of review in the summary 225 Action to consider extraneous inequitable

conduct alleged to void the written consents.

         The defendants in the 225 Action are all incumbent Board members (the

“Director Defendants”).4 They contend Brown’s Motion for Summary Judgment

must be denied so that the Court can consider their defense rooted in Brown’s and

Bartels’ alleged inequitable conduct. The Director Defendants also assert that the

written consents are not yet effective because SGRP did not send the prompt notice

to stockholders as required under 8 Del. C. § 228(e) and Rule 14c-2 of the Securities

Exchange Act of 1934. Finally, the Director Defendants moved to supplement the

summary judgment record with a May 2018 email from Brown that purportedly

“conceded the point” that notice is impracticable.5

         The Motion to Supplement is granted, but the subject materials do not affect

my analysis on the Motion for Summary Judgment, which is granted in part and

denied in part without prejudice to any of Brown’s claims. The 225 Action will

proceed to trial. Section 225 actions are narrow, summary proceedings to determine




4
 SGRP is plaintiff in the Bylaw Action and the Director Defendants are defendants in the
225 Action, but the two groups have related interests and retained the same counsel.
Accordingly, I refer to both SGRP and the Director Defendants loosely as the “SGRP
Parties” when they act together.
5
    Mot. to Supp. at ¶ 11.


                                           3
the in rem status of board and officer seats. At the same time, the Court must review

cognizable claims, including potential breaches of fiduciary duty, to the extent they

bear on the proper composition of the disputed offices. The Director Defendants

assert such claims and are entitled to develop them through trial. While I intend to

determine the 225 Action with a tailored analysis befitting its summary nature and

scope, I cannot wholly exclude, at this time and on an undeveloped record, the

Director Defendants’ defense that alleged breaches of fiduciary duty nullify the

written consents and bear on the composition of the Board.

      As for the written consents, I find that they were technically effective under

Section 228 upon their delivery on July 5, 2018, notwithstanding the Section 225

issues, referenced above, that will be addressed at trial. SGRP cannot nullify

otherwise effective written consents by unilaterally withholding notice of those acts.

Nor can SGRP justify withholding that notice by pointing to perceived conflicts

between SEC Rules and Delaware law.

I.    BACKGROUND
      The 225 Action and the Bylaw Action involve a series of purported corporate

acts from the summer of 2018. The parties dispute the impact of those acts on SGRP

and the current composition of its Board. I draw the background below from the

parties’ complaints and the uncontested facts from the briefing.




                                          4
          A.       The Parties
          SGRP is a Delaware merchandising and marketing services company based

out of New York and Michigan.6 As of June 29, 2018, the members of SGRP’s

Board were Bartels, Peter W. Brown, Christiaan M. Olivier, Arthur B. Drogue, Jack

W. Partridge, Kellar, and R. Eric McCarthey.7 SGRP’s governance committee

determined that Drogue, Partridge, McCarthey, and Kellar are independent

directors.8

          Brown, Bartels, and SGRP have a long history.9 Brown has held various

director and management positions in the company, including his most recent posts

as Chairman of the Board and an officer, which he retired from on May 3, 2018.10

Bartels has been Vice Chairman of the Board and an officer since 1999.11 Brown




6
 Verified Amended Complaint, Bylaw Action, at ¶ 4 (Sep. 21, 2018) (the “Bylaw
Complaint”).
7
 Id. at ¶ 8. Bartels is a defendant to the Bylaw Action. Peter W. Brown is related to
defendant Robert G. Brown. Id. at ¶ 5. I refer to the defendant Brown generally as
“Brown” in this decision. The remaining directors are the Director Defendants.
8
    Id. at ¶ 8.
9
  Allegations regarding that history are set forth in the Bylaw Action pleadings. That
history is not necessary for this decision. See id. at ¶¶ 15-57.
10
     Id. at ¶ 5.
11
     Id. at ¶ 6.



                                          5
and Bartels together own a majority of SGRP outstanding stock and it is undisputed

that they, at least collectively, are controlling stockholders.12

           B.      The Written Consents
           On June 29 and July 5, 2018, Brown and Bartels executed written consents

that together purported to remove Kellar from the Board and elect non-party Mayer

in his place (the “June 29 Consent” and “July 5 Consent,” or together, the “Director

Consents”).13 Also on July 5, the Board purported to adopt amended and restated

bylaws (the “July Bylaws”).14           Section 3.11 of the July Bylaws imposed a

requirement that “a majority of the members of the Board shall be independent

directors,” but also stated that:

           Notwithstanding any provision of [the Bylaws] or any size of or limited
           on the number of Board members established in any resolution of the
           Board or its stockholders to the contrary, the Board size shall be
           automatically expanded to accommodate each additional independent
           director needed to satisfy this majority requirement.15




12
     Id. at ¶ 7.
13
     Docket Item (“D.I.”) 1 at ¶ 10 (the “225 Complaint”).
14
     Bylaw Compl. at ¶ 55.
15
     Id.



                                              6
         Brown and Bartels delivered the July 5 Consent at approximately 11:26 a.m.,

before the Board met to approve the July Bylaws around 3:00 p.m.16 Brown

contends the Director Consents were effective upon delivery of the July 5 Consent.17

         On July 31, SGRP filed a preliminary information statement (the “Preliminary

Statement”) with the SEC to disclose the Director Consents. After a ten-day period

to allow the SEC to approve or comment, SGRP allegedly would have delivered the

Preliminary Statement to stockholders.18 But, on August 6, Brown and Bartels each

filed an amended Schedule 13D with the SEC, recognizing their status as a control

group for certain purposes and outlining several proposed bylaw amendments that

they intended to adopt by written consent.19 The SGRP Parties assert that these

filings rendered the Preliminary Statement inaccurate and that disclosing it to

stockholders would therefore be improper.20




16
  Opening Br. at 6; Kyle A. Pinder Affidavit, D.I. 35, Ex. A. While initially disputed, the
parties have agreed, in light of discovery, that Brown and Bartels delivered the Director
Consents before the Board approved the July Bylaws. See Opening Br. at 6-8; Answering
Br. at 11; Reply Br. at 1 n.1; Arg. Tr. at 12:24-13:18.
17
   225 Compl. at ¶ 10. The parties appear to agree that the June 29 Consent alone did not
represent a sufficient number of shares to effect the corporate action. See Bylaw Compl.
at Exs. D-E; Answering Br. at 11. The corporate action could only have been effective
upon delivery of the July 5 Consent.
18
     Bylaw Compl. at ¶ 69; Reply to Mot. to Supp. at ¶¶ 2, 6.
19
     Bylaw Compl. at Ex. G.
20
     Id. at ¶ 69; Answering Br. at 20.



                                              7
         On August 8, Brown and Bartels delivered a third written consent (the

“August 8 Consent”) purporting to enact the changes outlined in their August 6 SEC

filings. These included amending the bylaws to provide for supermajority Board

approval for certain actions, generally fix the size of the Board unless determined

otherwise by the stockholders, require stockholder approval for virtually all future

directors, and remove the July Bylaws’ requirement of a majority of independent

directors.21 The parties agree that the August 8 Consent did not become effective, if

it became effective at all, until a fourth written consent was delivered on September

18 (with the previous consents, the “Written Consents”).22

         C.     The Litigation
         SGRP brought the Bylaw Action on September 4 (as amended on September

21) to challenge aspects of the Written Consents, including through a declaratory

judgment and claims for conspiracy and breaches of the duty of loyalty. Brown

followed with the 225 Action on September 18, which seeks a ruling under Section

225 to settle the Board’s true composition. Both parties sought expedition, which

the Court granted on October 2.23 This case was then assigned to me on October 4.




21
     Bylaw Compl. at ¶¶ 66-67.
22
     Opening Br. at 3; Answering Br. at 13-14.
23
     D.I. 21.


                                             8
         In their second affirmative defense to Brown’s Section 225 complaint, the

Director Defendants assert:

         As is more fully set forth in SGRP’s Verified Amended Complaint
         [Transaction ID No. 62479682] in the [Bylaw Action], Plaintiff’s
         purported removal of Mr. Kellar and appointment of Mr. Mayer to the
         Board of SGRP are part of a larger, grossly inequitable scheme by
         Plaintiff and his co-controlling shareholder to improperly divert
         SGRP’s resources to their own purposes and for their sole benefit, in
         violation of their fiduciary duties to SGRP and to its minority
         shareholders. Regardless of whether Plaintiff’s actions described in its
         Complaint in this action were properly taken if the Court looks to the
         By-Laws in isolation, such inequitable actions do not become
         permissible simply because they are legally possible.24

         In the Bylaw Action, SGRP seeks the following relief that is potentially

relevant to the Director Defendants’ pleadings in this action:

              A declaratory judgment that the August 8 Consent’s bylaw

                 amendments, and “[a]ny further action by [Brown and Bartels] to

                 remove or attempt to remove any independent director,” are void or

                 voidable.25

              A ruling that Brown and Bartels owe fiduciary duties to SGRP and its

                 minority stockholders and breached those duties “[b]y seeking to




24
     See D.I. 18 at 6.
25
     Bylaw Compl. at ¶¶ 76-86.



                                            9
                 amend the By-Laws and entrench their control over SGRP so that they

                 can divert Company resources to themselves[.]”26

              A ruling that Brown and Bartels conspired to “entrench their control

                 over SGRP, strip the Board of its independence, misappropriate

                 Company assets for their own personal benefit, and harm SGRP and its

                 minority stockholders[.]”27

              Permanent injunctions severely limiting Brown’s and Bartels’ control

                 over SGRP, including “enjoining [Brown and Bartels] from . . .

                 removing or attempting to remove any independent director(s), [and]

                 taking or attempting to take any other action to weaken or attempt to

                 weaken the independence of SGRP’s Board or any of its

                 Committees[.]”28

         On November 14, Brown moved for summary judgment in the 225 Action.

The parties briefed the motion, and, on December 11, I heard argument. Discovery

is still ongoing.

         On December 13, the Director Defendants moved to supplement the summary

judgment record to include a May 17, 2018, email from Brown in which he



26
     Id. at ¶¶ 87-89.
27
     Id. at ¶¶ 90-94.
28
     Id. at 39-40.


                                               10
commented on the legal proceedings as described in a draft SGRP SEC filing. The

parties briefed the Director Defendants’ request and submitted the Motion to

Supplement for decision on December 19.

II.   ANALYSIS
      Brown seeks summary judgment on the grounds that the Director Consents

are technically valid and effective, and that the SGRP Parties’ allegations of inequity

are purely collateral to this Section 225 proceeding and cannot be considered as a

matter of law. The Director Defendants oppose summary judgment on the grounds

that Section 225 permits the Court to consider their defense of inequitable conduct

by Brown and Bartels, and that the Director Consents are not effective because

notice to the minority stockholders has not been given under Section 228(e) or Rule

14c-2 of the Securities Exchange Act of 1934.

      The parties focus on whether the Court may consider the alleged inequitable

conduct in the abstract under Section 225, rather than whether that conduct has been

proven and how it might apply to the Director Consents and the composition of the

Board. Discovery in this action is ongoing and trial is scheduled to begin in just over

a month. As a result, the Director Defendants continue to develop their defense of

the 225 Action: that purportedly inequitable conduct by Brown and Bartels render

the Director Consents voidable. The Director Defendants’ defense is not sufficiently

developed for a pre-trial merits ruling.



                                           11
         “There is no ‘right’ to a summary judgment.”29 “Summary judgment is

appropriate when the record shows that ‘there is no genuine issue as to any material

fact and that the moving party is entitled to a judgment as a matter of law.’”30 “The

moving party bears the burden of establishing that there are no issues of material

fact, and the court must review all evidence in the light most favorable to the non-

moving party.”31 “The Court maintains the discretion to deny summary judgment if

it decides that a more thorough development of the record would clarify the law or

its application.”32

         The Director Defendants acknowledged at argument that there are no material

disputed facts.33 Accordingly, the only questions presented on the Motion for

Summary Judgment are whether Brown is entitled to judgment as a matter of law,

and whether a more thorough development of the record would clarify the law or its

application.




29
     Telxon Corp. v. Meyerson, 802 A.2d 257, 262 (Del. 2002).
30
  Weil v. VEREIT Operating P’ship, L.P., 2018 WL 834428, at *3 (Del. Ch. Feb. 13, 2018)
(quoting Ct. Ch. R. 56(c)).
31
     Gary v. Beazer Homes USA, Inc., 2008 WL 2510635, at *3 (Del. Ch. June 11, 2008).
32
   Zimmerman v. Crothall, 2012 WL 707238, at *5 (Del. Ch. Mar. 5, 2012) (citations and
internal quotation omitted), as revised (Mar. 27, 2012).
33
     Arg. Tr. at 14:19-15:7.



                                            12
         Separately, and in the context of these expedited proceedings, I grant the

Motion to Supplement.34 Because I need not reach the question of why SGRP

declined to notify stockholders of the Director Consents, the evidence from the

Motion to Supplement does not inform my analysis.35

         A.     Because The Director Defendants Have Asserted Inequitable
                Conduct Bearing On The Board’s Composition, The 225 Action
                Will Continue To Trial.
         Brown asserts that summary judgment is appropriate because the Director

Defendants’ defense in the 225 Action that inequitable conduct by Brown and

Bartels render the Director Consents voidable, however developed, cannot be

cognizable under Section 225 as a matter of law. In particular, Brown rejects the

Director Defendants’ assertion that the seminal Schnell v. Chris-Craft Industries,

Inc.36 decision provides an additional equitable gloss on Section 225 that compels

this Court to consider Brown’s and Bartels’ inequitable conduct as broadly pled in




34
  “A motion to reopen and supplement the record is addressed to the discretion of the
Court.” Pope Investments LLC v. Benda Pharm., Inc., 2010 WL 3075296, at *1 (Del. Ch.
July 26, 2010). While “the admission of late-submitted evidence is not favored,” I
conclude that the lack of prejudice and considerations of judicial economy control in the
unique circumstances of this expedited, dual-track litigation. See id. (quoting TR Investors,
LLC v. Genger, 2009 WL 4696062, at *12 n.36 (Del. Ch. Dec. 9, 2009)).
35
     See infra at 30-31.
36
     285 A.2d 437 (Del. 1971).



                                             13
the 225 and Bylaw Actions. If Brown is right, the Director Consents’ technical

compliance with Section 228 is dispositive of the Board’s composition.37

         The Delaware Supreme Court summarized the scope of Section 225

proceedings in Genger v. TR Investors, LLC:

         A Section 225 proceeding is summary in character, and its scope is
         limited to determining those issues that pertain to the validity of actions
         to elect or remove a director or officer. “In determining what claims
         are cognizable in a [Section] 225 action, the most important question
         that must be answered is whether the claims, if meritorious, would help
         the court decide the proper composition of the corporation’s board or
         management team.” If not, then those claims “are said to be ‘collateral’
         to the purpose of a [Section] 225 action and must be raised in a
         [separate] plenary action.”38

         Section 225 proceedings are in rem, “where the ‘defendants’ are before the

court, not individually, but rather, as respondents being invited to litigate their claims

to the res (here, the disputed corporate office) or forever be barred from doing so.”39

That in rem nature limits what the Court can decide under Section 225. For instance,

this Court may adjudicate a “claim that a director-respondent does not validly hold

corporate office because that director obtained the office through fraud, deceit, or




37
     I address the Section 228 issues below, infra at 20-32.
38
  Genger v. TR Inv’rs, LLC, 26 A.3d 180, 199 (Del. 2011) (alterations in original) (quoting
Agranoff v. Miller, 1999 WL 219650, at *17 (Del. Ch. Apr. 12, 1999)).
39
 Id. at 199-200; see Levinhar v. MDG Med., Inc., 2009 WL 4263211, at *11-12 (Del. Ch.
Nov. 24, 2009) (barring claims that were not properly raised in prior Section 225 action).



                                               14
breach of contract. . . . but only for the limited purpose of determining the

corporation’s de jure directors and officers.”40

         Section 225’s scope is narrow, but Brown incorrectly posits “that allegations

of inequitable conduct should not and cannot be injected into a Section 225 action,

particularly where it is undisputed that the corporate action was taken by a majority

of stockholder votes.”41 Delaware courts reject the notion that “rigid, inflexible rules

preclude this court from hearing anything but the narrowest arguments in Section

225 cases.”42 Instead, “the question [of] whether an issue is properly litigable in a

Section 225 action turns . . . upon a determination of whether it is necessary to decide

in order to determine the validity of the election or designation by which the

defendant claims to hold office.”43 Issues beyond that are collateral to the narrow

scope of a Section 225 proceeding and may not be considered.44




40
     Genger, 26 A.3d at 200.
41
     Opening Br. at 10.
42
     Levinhar, 2009 WL 4263211, at *11.
43
  Kahn Bros. & Co. Profit Sharing Plan & Tr. v. Fischbach Corp., 1988 WL 122517, at
*5 (Del. Ch. Nov. 15, 1988).
44
   See Frankino v. Gleason, 1999 WL 1032773, at *3 (Del. Ch. Nov. 5, 1999) (“Section
225 proceedings are necessarily narrow in scope in order to provide clear and quick
relief. The Court of Chancery has historically been reluctant to entertain collateral issues
that would take a Section 225 proceeding outside the narrow confines contemplated by
Delaware law.”), aff’d sub nom. McNamara v. Frankino, 744 A.2d 988 (Del. 1999).



                                            15
                1.     Schnell Is Consistent With Section 225.
         The parties dispute how, if at all, Schnell informs the scope of inquiry under

Section 225. In Schnell, the Delaware Supreme Court rejected a company’s attempt

to thwart dissident stockholders by changing the annual meeting date, holding “that

inequitable action does not become permissible simply because it is legally

possible.”45 Brown asserts that the narrow scope of Section 225 cannot include the

broad principles in Schnell. His interpretation of Delaware law paints a restrictive

view of the claims that may arise in this proceeding.46

         If Section 225 demanded only technical compliance with statutory consent

requirements, then I would grant Brown’s Motion. But this Court has applied

Schnell’s equitable principles in Section 225 actions. For instance, in Gassis v.

Corkery, the Court considered whether the plaintiff director’s removal was voidable

under Section 225 as either an impermissible retaliation for the director exercising



45
     Schnell, 285 A.2d at 439.
46
  Brown relies on: Box v. Box, 697 A.2d 395, 398 (Del. 1997) (“To preserve an expedited
remedy, a proceeding brought pursuant to section 225 is a summary proceeding, and the
Court of Chancery has consistently limited section 225 trials to narrow issues.”); Frankino,
1999 WL 1032773, at *3 (“Section 225 proceedings are necessarily narrow in scope in
order to provide clear and quick relief. The Court of Chancery has historically been
reluctant to entertain collateral issues that would take a Section 225 proceeding outside the
narrow confines contemplated by Delaware law.”); and Bachmann v. Ontell, 1984 WL
21204, at *1 (Del. Ch. Nov. 7, 1984) (rejecting “an affirmative defense [that] attempt[ed]
to inject into the proceeding a collateral matter which is not within the contemplation of
the statute under which the summary proceeding [had] been brought”).



                                             16
his Section 220 rights or breaches of fiduciary duty by the directors who removed

the plaintiff from the board. Consistent with Genger, both issues related directly to

the composition of the board.47 Gassis serves as an example of this Court’s ability

to review appropriate claims of inequitable conduct within the boundaries of Section

225.48

         In light of Genger and other precedent, I reject Brown’s cramped view of this

action and conclude that existing law on Section 225 permits the adjudication of

inequitable conduct, as encouraged by Schnell, so long as those issues are germane

to determining the composition of the Board. Courts weighing claims under Section

225 must consider cognizable allegations of fraud, deceit, breach of contract, breach

of fiduciary duty,49 and other claims that “if meritorious, would help the court decide



47
   Gassis v. Corkery, 2014 WL 2200319, at *14-16 (Del. Ch. May 28, 2014), aff’d, 113
A.3d 1080 (Del. 2015). I am not persuaded by Brown’s attempt to distinguish Gassis on
the grounds that the corporation involved was a charitable corporation. Opening Br. at 9.
Brown concedes that Gassis reviewed the claims in question “because the Court was
reviewing whether the directors breached their fiduciary duties by removing their fellow
director.” Reply Br. at 8 n.11.
48
  Gassis, 2014 WL 2200319, at *14-16; see also Red Oak Fund, L.P. v. Digirad Corp.,
2013 WL 5740103, at *11 (Del. Ch. Oct. 23, 2013) (considering a breach of fiduciary duty
theory under Section 225).
49
   Gassis, 2014 WL 2200319, at *14-16 (deciding issue of whether “the removal [of a
director] constituted a breach of duty” in the context of Section 225); Red Oak Fund, L.P.,
2013 WL 5740103, at *10 (“One of the most frequent theories under which stockholders
have asked this Court to find an election invalid is a breach of fiduciary [duty] theory—in
particular, a claim that the company and the board of directors made material misstatements
or omissions during the proxy solicitation process.”).



                                            17
the proper composition of the corporation’s board or management team.”50 As a

result, the Court must review issues that could infect the composition of a company’s

“de jure directors and officers” under Section 225, notwithstanding formal

compliance with the voting procedures and requirements for those offices.51

         Schnell empowers this Court to look at both technicalities and equities.52

Section 225’s jurisprudence, although narrower in scope, echoes that doctrine. I

read Delaware’s existing law on Section 225 to embody an appropriately tailored

version of the foundational principle “that inequitable action does not become

permissible simply because it is legally possible.”53


50
   Agranoff, 1999 WL 219650, at *17; see also Genger, 26 A.3d at 199-200 (same);
Levinhar, 2009 WL 4263211, at *11 (rejecting argument that “rigid, inflexible rules
preclude this court from hearing anything but the narrowest arguments in Section 225
cases,” and noting that “[c]onsistent with what one would expect of a court of equity, this
court has even permitted litigation over whether a stockholder had obtained his stock by
defrauding the corporation”).
51
     Genger, 26 A.3d at 200.
52
   See generally Frederick Hsu Living Tr. v. ODN Holding Corp., 2017 WL 1437308, at
*10 (Del. Ch. Apr. 14, 2017) (stating that Delaware law follows the framework that “in
every case, corporate action must be twice tested: first, by the technical rules having to do
with the existence and proper exercise of the power; second, by equitable rules” (quoting
Adolf A. Berle, Corporate Powers as Powers in Trust, 44 Harv. L. Rev. 1049, 1049
(1931))), as corrected (Apr. 24, 2017); Paige Capital Mgmt., LLC v. Lerner Master Fund,
LLC, 2011 WL 3505355, at *16 (Del. Ch. Aug. 8, 2011) (“[A]s is standard in the
examination of a business law case challenging the actions of a fiduciary, I first determine
whether the fiduciary had the legal authority to make the decision in question, the source
of the legal authority in this case being a contract. After doing that, I determine whether,
assuming there was proper legal authority, that authority was used in conformity with the
fiduciary duties owed by the fiduciary.”).
53
     Schnell, 285 A.2d at 439.



                                             18
                 2.     The Director Defendants’ Defense May Be Cognizable Under
                        Section 225.
         Brown moved for summary judgment on the theory that the Director

Defendants’ defense is fundamentally not cognizable as a matter of law under

Section 225. Given the expedited nature of this action, the Director Defendants’

defense continues to incubate in discovery.54 In light of that timing and the contours

of Section 225 that guide review in this matter, summary judgment turns on whether

the Director Defendants have alleged as their defense sufficiently cognizable claims

of inequitable conduct that may impact the composition of the Board.

         I conclude that Brown is not entitled to judgment as a matter of law because

the Director Defendants asserted, at this early stage, a sufficiently cognizable

equitable defense under Section 225.55 Their affirmative defense alleges inequitable

conduct that, once developed, may affect the Director Consents and Brown’s

requested Board composition.56 The Director Defendants are entitled to develop and



54
  When Brown filed the Motion, the parties had yet to issue responses and objections to
outstanding interrogatories. Even now, the parties continue to produce documents.
55
     See supra at 9; D.I. 18 at 6.
56
   Although I find the Direct Defendants’ defense sufficiently cognizable to deny the
Motion as discovery continues, I do not rule today on whether those allegations are
ultimately cognizable under Section 225. Once fully developed, they may fail to relate
enough to the Director Consents and the composition of the Board to be cognizable. See,
e.g., Frankino, 1999 WL 1032773, at *3; Bachmann, 1984 WL 21204, at *1. But that
determination is not appropriate before the close of discovery in a summary proceeding.
See Zimmerman, 2012 WL 707238, at *5 (“The Court maintains the discretion to deny



                                          19
test those allegations at trial. They need not prove them further at this stage when

discovery is still ongoing.

      The Motion is denied without prejudice to Brown’s arguments on this issue.

The 225 Action will proceed to trial immediately before the Bylaw Action.57 The

Court will determine the extent to which Brown’s and Bartels’ alleged inequitable

conduct informs the composition of the Board with the benefit of a more developed

record.

      B.     The Director Consents Were Effective Upon Delivery On July 5,
             2018.
      The Motion for Summary Judgment also presents a more classic Section 225

dispute: whether the Director Consents were effective under Section 228. Brown

asserts that they were effective upon delivery of the July 5 Consent. The Director

Defendants counter that the Director Consents are not yet effective because the

minority stockholders have not received notice of the corporate action.




summary judgment if it decides that a more thorough development of the record would
clarify the law or its application.”).
57
  Levinhar, 2009 WL 4263211, at *9 (“[P]arties may press a Section 225 action, file a
companion complaint, and have the court consolidate those actions for a simultaneous trial
when claims triable in a Section 225 action might provide a basis for broader relief.”).



                                           20
            1.     The Director Consents Were Effective Under Section 228
                   Upon Delivery.
      Section 228 authorizes corporate actions by written consent and sets out the

related notice requirements:

      (a) Unless otherwise provided in the certificate of incorporation, any
      action required by this chapter to be taken at any annual or special
      meeting of stockholders of a corporation, or any action which may be
      taken at any annual or special meeting of such stockholders, may be
      taken without a meeting, without prior notice and without a vote, if a
      consent or consents in writing, setting forth the action so taken, shall be
      signed by the holders of outstanding stock having not less than the
      minimum number of votes that would be necessary to authorize or take
      such action at a meeting at which all shares entitled to vote thereon were
      present and voted and shall be delivered to the corporation . . . .

      (e) Prompt notice of the taking of the corporate action without a
      meeting by less than unanimous written consent shall be given to those
      stockholders or members who have not consented in writing and who,
      if the action had been taken at a meeting, would have been entitled to
      notice of the meeting if the record date for notice of such meeting had
      been the date that written consents signed by a sufficient number of
      holders or members to take the action were delivered to the corporation
      as provided in this section[.]

      The parties appear to agree that the Director Consents complied with all the

provisions of Section 228 except for the prompt notice required under Section

228(e). At issue, then, is whether the absence of notice under Section 228(e)

prevents an otherwise valid written consent from taking effect.

      “Because [Section] 228 clearly and unambiguously permits a majority of the

stockholders of a corporation to act immediately and without prior notice to the




                                          21
minority, the statute must be given its plain meaning.”58 The first sentence of Section

228 provides that corporate action by written consent “may be taken without a

meeting, without prior notice and without a vote[.]”59 That plain language indicates

that notice is not a condition precedent to an effective written consent. By contrast,

other sections of Section 228 are conditions to effective corporate action. Section

228(a) provides that written consents may replace a stockholder meeting only “if”

certain conditions are met, and Section 228(c) states that “[n]o written consent shall

be effective . . . unless” the consents are properly delivered.60              Unlike those

provisions, Section 228(e) does not present notice as a condition precedent to an

effective written consent.

         Delaware case law confirms that reading. This Court has held that, generally,

“a certificate [of incorporation] amended by written consent takes effect . . . even




58
     Allen v. Prime Computer, Inc., 540 A.2d 417, 420 (Del. 1988).
59
     8 Del. C. § 228(a) (emphasis added).
60
   Id. (stating that corporate active by written consent “may be taken without a meeting,
without prior notice and without a vote, if a consent or consents in writing, setting forth the
action so taken, shall be signed by the holders of outstanding stock having not less than the
minimum number of votes that would be necessary to authorize or take such action at a
meeting at which all shares entitled to vote thereon were present and voted and shall be
delivered to the corporation”); id. at § 228(c) (stating that “[n]o written consent shall be
effective to take the corporate action referred to therein unless written consents signed by
a sufficient number of holders or members to take action are delivered to the corporation
in the manner required by this section within 60 days of the first date on which a written
consent is so delivered to the corporation”).



                                              22
before prompt notice is given.”61 That is because a written consent “permits

immediate action”62 and is “effective [] upon the delivery of the proper number of

valid and unrevoked consents to the corporation.”63 “The action is effective when a

legally sufficient consent (or consents) is delivered to the corporation at either its

registered office in the State of Delaware or its principal place of business.”64

“[S]tockholders have the right . . . in the case of action taken by written consent, to

receive prompt notice after the fact of the action taken.”65 I conclude that Section

228(e)’s notice requirement is not a condition precedent or prerequisite to a

corporate action by written consent, but rather an additional obligation resulting

from that corporate action.

         Prompt notice to the minority stockholders is of critical importance. Failure

to provide that notice has, in unique circumstances, compelled the Court to deviate

from the default rule that written consents are effective upon delivery. This Court

has refused to enforce a certificate of incorporation amended by written consent


61
     Di Loreto v. Tiber Holding Corp., 1999 WL 1261450, at *5 (Del. Ch. June 29, 1999).
62
   Espinoza v. Zuckerberg, 124 A.3d 47, 57 (Del. Ch. 2015) (quoting Carsanaro v.
Bloodhound Techs., Inc., 65 A.3d 618, 641 (Del. Ch. 2013)).
63
 Allen, 540 A.2d at 420; see also Edward P. Welch, et al., 2 Folk on the Delaware General
Corporation Law § 228.03 (6th ed.) (“Section 228 authorizes immediate stockholder action
without a meeting[.]”).
64
  1 R. Franklin Balotti & Jesse A. Finkelstein, The Delaware Law of Corporations and
Business Organizations § 7.29 (3d ed. Supp. 2018).
65
     Zuckerberg, 124 A.3d at 58.



                                            23
under Section 228 when the company delayed notice to the non-consenting

stockholders for months, until the failure to provide notice was remedied.66 In Di

Loreto v. Tiber Holding Corporation, the Court acknowledged that a certificate of

incorporation amended by written consent normally takes effect upon its proper

filing even before prompt notice is given, but found that the circumstances in that

case justified making enforcement of the amendment dependent on notice.

           Di Loreto involved a peculiar set of facts. Majority stockholders, aligned with

the company, delivered a written consent to strip a share buyback provision from the

certificate of incorporation.67 That provision was the subject of separate litigation

between the company and the plaintiff minority stockholders, but the company did

not notify those stockholders of the written consent. The company also did not file

the amended certificate until months after the written consent, and did so only when

the minority stockholders made a demand under the buyback provision.68

           Di Loreto’s primary ruling was that plaintiffs’ buyback demand was effective

because they made it before the company filed the amended certificate of

incorporation.69 But the Court also found that the company’s months-long delay in



66
     See id. at 57; Di Loreto, 1999 WL 1261450, at *1-4.
67
     Di Loreto, 1999 WL 1261450, at *1-4.
68
     Id.
69
     Id.



                                             24
notifying plaintiffs of the purportedly amended certificate of incorporation,

especially in the midst of litigation about the buyback provisions, precluded

enforcement of those amended provisions until the company gave plaintiffs notice

under Section 228.70 In so doing, the Court acknowledged that action by consent did

not usually depend on notice, but held that the company’s actions merited an

exception to that rule.71

          This case falls under the rule, not the Di Loreto exception. In Di Loreto, the

majority stockholders enacting the written consent were aligned with the company

against the minority stockholder plaintiffs, and the lack of notice prevented those

plaintiffs from reacting promptly to the majority’s written consent. In this case, the

factions are aligned in the opposite configuration. Brown and Bartels acted by

written consent, but SGRP opposes that corporate action and has independently

declined to notify the stockholders, claiming that the lack of notice stops the consents

from being effective.

          Di Loreto applied its exception as a shield to protect the minority stockholder

plaintiffs. Where the parties acting by written consent clash with the companies that




70
     Id. at *5.
71
  Id. (“Although a certificate amended by written consent takes effect upon proper filing
even before prompt notice is given, failure to give notice promptly may in certain instances,
such as this one, preclude enforcement of the amended provisions—at least until it is filed
and notice is actually given.”).


                                             25
must deliver the notice, as here, applying Di Loreto’s exception would grant the

companies a sword with which to delay or thwart written consents by slow-rolling

notice to the stockholders.       The consequences of withholding notice in those

circumstances should be borne by the company, not the stockholders exercising their

right to act by written consent.72 SGRP’s failure to give notice does not stymie the

otherwise effective Director Consents. I conclude that Section 228 applies as written

and the Director Consents were effective, at least in terms of technical compliance

with Section 228, on July 5. The Motion is granted as to that narrow issue.

                2.    Rule 14c-2 Of The Exchange Act Does Not Preclude The
                      Effective Written Consents Under Section 228.
         The Director Defendants claim that Rule 14c-2 of the Securities Exchange

Act of 1934 provides an independent notice requirement that precludes effective

Director Consents until notice is given, but at the same time prevents SGRP from

giving that notice.73 The Director Defendants assert that Brown and Bartels, by filing


72
  See, e.g., Zuckerberg, 124 A.3d at 58 (“[S]tockholders have the right to participate in a
meeting at which a vote is to be taken after receiving notice and all material information
or, in the case of action taken by written consent, to receive prompt notice after the fact of
the action taken.”); In re Nine Sys. Corp. S’holders Litig., 2014 WL 4383127, at *37 (Del.
Ch. Sept. 4, 2014) (holding that failure to give adequate notice under Section 228(e) of
written consent to amend company’s governing documents was “powerful evidence of
unfair dealing” and “inconsistent with the Board’s fiduciary duties,” but not finding any
impact on the effectiveness of the corporate action), abrogated on other grounds by
Sciabacucchi v. Liberty Broadband Corp., 2018 WL 3599997, at *10 (Del. Ch. July 26,
2018).
73
     See Answering Br. at 18-20; 17 C.F.R. § 240.14c-2.



                                             26
amended Schedule 13Ds on August 6,74 interrupted the ten-day period during which

the SEC was to review the Preliminary Statement. As a consequence, the Director

Defendants argue, the Preliminary Statement was never approved by the SEC and is

no longer sufficiently accurate to disclose to SGRP’s stockholders.75 The Director

Defendants conclude that, under Rule 14c-2, the lack of notice to stockholders

precludes the Director Consents underlying that Preliminary Statement from taking

effect, a situation for which “Brown and Bartels have only themselves to blame.”76

Brown counters that the SEC recently cast doubt on the Director Defendants’

interpretation of the Exchange Act.77

         The portion of Rule 14c-2 that the Director Defendants rely upon provides

that:

         (a)(1) In connection with . . . the taking of corporate action by the
         written authorization or consent of security holders, the registrant shall
         transmit to every security holder of the class that is entitled to vote or
         give an authorization or consent in regard to any matter to be acted upon
         and from whom proxy authorization or consent is not solicited on behalf
         of the registrant pursuant to section 14(a) of the [Exchange] Act: (i) A
         written information statement containing the information specified in
         Schedule 14C (§ 240.14c–101);

74
     See supra at 7.
75
     See Answering Br. at 18-20.
76
     See id.
77
   See Reply Br. at 4-5 (citing Letter from CBS Corp. to SEC (June 7, 2018),
 https://www.sec.gov/Archives/edgar/data/813828/000089882218000041/filename1.htm;
CBS Corp., SEC Comment Letter, File No. 001-09553 (June 13, 2018),
https://www.sec.gov/Archives/edgar/data/813828/000000000018018332/filename1.pdf).



                                            27
       ....

       (b) The information statement shall be sent or given at least 20 calendar
       days prior to the meeting date or, in the case of corporate action taken
       pursuant to the consents or authorizations of security holders, at least
       20 calendar days prior to the earliest date on which the corporate action
       may be taken.78

       Neither side briefed the scope of this Court’s jurisdiction to interpret and apply

Rule 14c-2.79 I assume, without deciding, that the Court has jurisdiction to consider

how a federal notice provision might inform the validity of the Director Consents

under Delaware law. The parties agree that the Exchange Act Rules in play do not

preempt Delaware law.80 To the extent the Exchange Act might compel a different


78
   17 C.F.R. § 240.14c-2. The Director Defendants purport that the Rule 14c-2 information
statement is required to disclose, among other things, “members of the Board if any action
is to be taken with respect to the election of directors . . . . a description of any amendment
to the bylaws and the reasons and general effect of such amendments . . . . any matter in
which any director or nominee or affiliated person of such director or nominee is a party
adverse to SGRP or has a material interest adverse to SGRP . . . . [and] information
regarding corporate governance, including such matters as the independence of members
of the Board[.]” Answering Br. at 22-23.
79
  See In re Ebix, Inc. S’holder Litig., 2014 WL 3696655, at *17 (Del. Ch. July 24, 2014)
(holding that the Court of Chancery did not have subject matter jurisdiction over claim
based on federal securities laws).
80
   See Reply Br. at 4-5; Reply to Mot. to Supp. at ¶ 7 n.3. That agreement comports with
Delaware law. This Court has routinely held that the Exchange Act’s policies of
stockholder enfranchisement and notice complement and mirror those in Delaware law.
See, e.g., Rich v. Fuqi Int’l, Inc., 2012 WL 5392162, at *4 (Del. Ch. Nov. 5, 2012) (holding
that federal procedure to request exemption from proxy rules did not “affect the principles
and goals of SEC proxy rules, which are still to protect the stockholder franchise and
provide accurate information to stockholders,” and that “[i]f anything, the [procedure] has
actually harmonized Delaware and federal law by . . . reducing the likelihood of any
outright conflict between the annual meeting requirement and the proxy rules”); Esopus
Creek Value LP v. Hauf, 913 A.2d 593, 606 (Del. Ch. 2006) (“[T]he overriding purpose of



                                              28
result than Section 228, “the important policies underlying the internal affairs

doctrine [suggest] that the power of the state of incorporation . . . not be lightly

overturned.”81 My application of Section 228 to the Director Consents is not affected

by Rule 14c-2.

         Even if Rule 14c-2 imposes a notice requirement beyond that found in Section

228, the Director Consents would still be effective under Delaware law. This Court

has consistently found that corporations cannot avoid their obligations under

Delaware law, like holding annual meetings, by pointing to additional or purportedly

conflicting obligations under Rule 14 of the Exchange Act.82 Those cases apply here

in the related context of the stockholder franchise and notice under Section 228(e).

The Director Consents remain effective insofar as they satisfied Section 228(e), and

the Director Defendants cannot defeat that compliance with Delaware law by




federal regulation of the corporate proxy solicitation process is to protect shareholder
voting rights.”); Newcastle Partners, L.P. v. Vesta Ins. Grp., Inc., 887 A.2d 975, 981 (Del.
Ch. 2005) (“Nothing in either [the Exchange Act] or regulation suggests any purpose to
interfere with the power of state courts to require that stockholder meetings be held in
accordance with the requirements of state corporation law in situations where the registrant
. . . is unable to comply with the literal terms of the SEC proxy rules.”), aff’d, 906 A.2d
807 (Del. 2005).
81
     Newcastle Partners, L.P., 887 A.2d at 981.
82
   See Fuqi Int’l, Inc., 2012 WL 5392162, at *2-4; Newcastle Partners, L.P., 887 A.2d at
979-82; see also Williams v. Calypso Wireless, Inc., 2012 WL 424880, at *3 (Del. Ch. Feb.
8, 2012) (collecting “Delaware decisions addressing this recurring issue”).



                                             29
expressing concern over SGRP’s ability to give notice under Rule 14c-2 in this

context.

         One additional dispute related to the Exchange Act remains. The Director

Defendants argue that any notice they could give to stockholders regarding the

Director Consents would be misleading or incomplete under Rule 14c-2 and

Delaware law in light of the evolving issues raised in the 225 and Bylaw Actions.83

They posit “that they should not be required to issue a notice exposing the company

and its directors to the risk of litigation arising from that notice.”84 For the first time

in their Reply to the Motion to Supplement, the Director Defendants assert that

“[u]ltimately, the issue before the Court distills to this: Should this Court direct

SGRP to issue the notice required under Section 228(e) in order to make the consents

effective under [Zuckerberg] and, if so, what information should that notice

contain?”85

         That issue is not before me. No party in the 225 or Bylaw Action seeks an

order or declaration regarding SGRP’s notice obligations. The question of notice is

only relevant in the 225 Action insofar as the Director Defendants assert that the


83
  See Answering Br. at 20-23; Reply to Mot. to Supp. at ¶¶ 2, 6. The Director Defendants
argue that Brown conceded this point when he expressed concern about the way legal
disputes were described in a draft SGRP SEC filing. See Mot. to Supp. at Ex. A.
84
     Reply to Mot. to Supp. at ¶ 7 n.3; see also Answering Br. at 20-23.
85
     Reply to Mot. to Supp. at ¶ 8.



                                              30
Director Consents are ineffective due to the lack of notice. Contrary to the Director

Defendants’ phrasing of the issue, I need not mandate notice under Section 228(e)

“in order to make the consents effective.”86 I have ruled that the Director Consents

were effective on July 5, and that notice under Section 228(e) is an additional

company obligation flowing from—not a condition precedent to—that corporate

action. Having addressed the live issues under Section 228, I do not reach at this

time whether the Director Defendants are acting prudently under Delaware law by

withholding notice.87

         There is a more fundamental problem with the Director Defendants’ argument

as it relates to the interaction between federal and Delaware law. “[A] rule meant to

reinforce management accountability to stockholders [cannot] be used as a tool to

indefinitely deprive stockholders of the franchise.”88 Here, the Director Defendants

offer Rule 14c-2 as a basis to avoid giving stockholders notice.89 Their position

appears to be that the interlocking requirements in Rule 14c-2 and Section 228



86
     See id.
87
  See XI Specialty Ins. Co. v. WMI Liquidating Tr., 93 A.3d 1208, 1220 (Del. 2014) (“As
noted, our courts do not issue advisory opinions.”).
88
     Fuqi Int’l, Inc., 2012 WL 5392162, at *3.
89
   Without reaching a ruling on the substance of Rule 14c-2, I note that even Director
Defendants’ interpretation of the regulation provides for a notice period ideally far shorter
than the nearly six months that have passed since Brown and Bartels delivered the Director
Consents. See Answering Br. at 18-20.



                                             31
operate so as to essentially preclude SGRP from making any disclosure to the

stockholders on the Director Consents in this situation.90 “Such a position stands the

purpose of corporate and securities law on its head.”91 Permitting the Director

Defendants to indefinitely delay adequate notice to stockholders under Rule 14c-2

and Section 228, each of which independently encourages that notice, would pervert

the incentives of both the SEC regulations and Delaware law. Accordingly, the

Director Defendants’ arguments regarding Rule 14c-2 do not inform my rulings on

Section 228.

III.     CONCLUSION
           For the foregoing reasons, the Director Defendants’ Motion to Supplement

the Summary Judgment Record is GRANTED, and the Motion for Summary

Judgment is GRANTED in part and DENIED in part without prejudice to Brown’s

claims. This action will proceed to trial on the remaining issues.

         IT IS SO ORDERED.




90
     Or, at least, that the disclosure would be “imprudent.” Id. at 20-23.
91
  Fuqi Int’l, Inc., 2012 WL 5392162, at *4. The Director Defendants have also not raised
whether they attempted to request an exemption from the SEC related to their notice
concerns. See Esopus Creek Value LP, 913 A.2d at 606 (where party claimed that
conflicting SEC rules prevented a stockholder vote, finding that “[g]iven the mutually
reinforcing purposes of these state and federal laws, there is reason to suppose that the SEC
will duly consider a request for exemptive relief”).


                                               32
